Trial Profile
A Phase II study to evaluate ABC294640 as a radioprotectant to prevent mucositis and radiation enhancer in cancer patients undergoing radiotherapy
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2016
Price :
$35
*
At a glance
- Drugs Opaganib (Primary)
- Indications Cancer; Head and neck cancer; Radiation-induced abnormalities
- Focus Therapeutic Use
- Sponsors RedHill Biopharma
- 01 Mar 2016 According to a RedHill Biopharma media release, this trial is expected to be initiated in second half of 2016.
- 06 Apr 2015 New trial record